メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
中野 卓二
医学部・消化器内科学・第１
h-index
407
被引用数
12
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2008
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(27)
類似のプロファイル
(6)
フィンガープリント
Takuji Nakanoが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Endoscopic Ultrasound
100%
Acoustic Radiation
50%
Cystic Pancreatic Lesion
50%
Chronic Hepatitis C
50%
Neoplasm
40%
Intraductal Papillary Mucinous Tumor
30%
Hepatocellular Carcinoma
29%
Liver Biopsy
29%
Transient Elastography
29%
Diagnosis
27%
Chronic Hepatitis B
25%
Extrahepatic Bile Duct Obstruction
25%
Interferon
25%
Hypoalbuminemia
25%
Biloma
25%
Liver Cirrhosis
25%
Polyp
25%
MALT Lymphoma
25%
Branched Chain Amino Acid
25%
Cholangitis
25%
Cholestasis
25%
Hepatitis C Virus
25%
Common Bile Duct
25%
Bile Duct
25%
Nalfurafine
25%
Recurrent Disease
25%
Fibrosis
25%
Cisplatin
25%
Intraarterial Drug Administration
25%
Confocal Laser Scanning Microscopy
25%
Transcatheter Arterial Chemoembolization
25%
Antiviral Therapy
25%
Ribavirin
21%
Biopsy
17%
Patatin
16%
Phospholipase
16%
Endoscopic Retrograde Cholangiopancreatography
15%
Bile Duct Cancer
12%
Pancreas Disease
12%
Prothrombin Time
11%
Liver Fibrosis
10%
Common Bile Duct Stone
10%
Vascularity
10%
Cytotechnology
10%
Tumor Biopsy
10%
Extrahepatic Bile Duct
10%
Fine-Needle Aspiration
7%
Disease
7%
Malignant Neoplasm
7%
Pancreas Adenocarcinoma
7%
Keyphrases
Endoscopic Ultrasonography
30%
Intraductal Papillary mucinous Neoplasm
30%
Chronic Hepatitis B
25%
Antiretroviral Therapy
25%
Medical Ultrasonics
25%
Efficacy Predictor
25%
Atezolizumab Plus Bevacizumab
25%
Liver Stiffness
25%
Biloma
25%
Bilirubin
25%
Intrahepatic Cholestasis
25%
Shear Wave Velocity
25%
Interferon-based Therapy
25%
Branched-chain Amino Acid Granules
25%
I148M
25%
PNPLA3
25%
Hepatitis B Envelope Antigen
25%
Acoustic Radiation Force Impulse Elastography
25%
Acoustic Radiation Force Impulse
25%
Stiffness Index
25%
Chronic Pruritus
25%
Nalfurafine Hydrochloride
25%
Contrast-enhanced Harmonic Endoscopic Ultrasonography
25%
Pancreatic Cyst
25%
Nutritional Status Assessment
25%
Intrahepatic Distant Recurrence
25%
Erythropoietic Protoporphyria
25%
Endoscopic Ultrasound
25%
Mural Nodule
19%
Hepatitis B Surface Antigen Levels
18%
Hepatocellular Carcinoma Progression
18%
Nalfurafine
18%
Fibrosis-4 (FIB-4)
16%
Nutritional Risk Index
16%
End of Treatment
15%
Transcatheter Arterial Infusion
14%
Article Use
12%
Hepatitis B e Antigen (HBeAg)
12%
Sustained Virological Response
12%
Bile Duct Tumor
12%
Subjective Global Assessment
12%
Arm muscle Circumference
12%
Precore mutant
10%
Fibrosis Stage
10%
Vascular Function
10%
Contrast-enhanced Harmonic EUS
10%
Resistance-associated Variants
8%
Albumin Infusion
8%
Hepatocellular Carcinoma Treatment
8%
Combined Index
8%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
54%
Phospholipase
41%
Nonalcoholic Fatty Liver
25%
Antiviral Therapy
25%
Recurrent Disease
25%
Cisplatin
25%
Hepatitis B Antigen
25%
Interferon
25%
Extrahepatic Bile Duct Obstruction
25%
Hypoalbuminemia
25%
Chemotherapy
25%
Bevacizumab
25%
Alpha Fetoprotein
25%
Nalfurafine
25%
Atezolizumab
25%
Chronic Hepatitis C
25%
Branched Chain Amino Acid
25%
Alpha Tocopherol
25%
Erythropoietic Protoporphyria
25%
Disease
22%
Ribavirin
21%
Aspartate Aminotransferase
20%
Alanine
16%
Focused Ion Beam
16%
Guanosine Triphosphate
12%
Serum Albumin
10%
Hepatitis B(e) Antigen
10%
Gamma Glutamyltransferase
9%
Recurrence Risk
8%
Epirubicin
8%
Progression Free Survival
6%
Erythrocyte Protoporphyrin
6%
Prothrombin
5%
Hepatitis B Virus Genotype C
5%
Acute Hepatitis B
5%
